Bruce Quinn, M.D., Ph.D., is a national leader on Medicare policy, the impact of health reform on innovation and the crafting of successful business strategies within the U.S. health care reimbursement system. He is a member of FaegreBD Consulting’s health and biosciences team and leads the reimbursement consulting practice. But with a unique set of skills, Dr. Quinn also provides significant synergies with the firm’s health care, intellectual property, life sciences and government advocacy groups.
With a nationwide client base, Dr. Quinn has worked successfully with both large and small companies in overcoming hurdles to commercialization through negotiation, understanding insightful ways to use the existing system to advantage and the mechanisms of policy change. Since 2008, he has been a full-time business strategist working with attorney and policy teams for both health care and life sciences clients.
Dr. Quinn travels nationwide to speak on health reform issues and publishes actively, most recently writing several peer-reviewed policy articles on advanced diagnostics and a series of authoritative white papers on the 2012-2014 coding reform process for genomic tests.
Before joining FaegreBD Consulting, Dr. Quinn was a senior health policy advisor with Foley Hoag after serving as the regional Medicare medical director for the California Part B program, where he had authority for final coverage decisions on approximately 15 percent of the U.S. Medicare program. Earlier in his career, Dr. Quinn was a physician executive in the health and life sciences division of Accenture, working with the pharma, biotech and genomics industries.
Dr. Quinn is a board-certified pathologist. As a physician-scientist on the faculty of Northwestern University School of Medicine, he led pathology research for Northwestern’s NIH-funded Alzheimer Research Center. Dr. Quinn has also held academic positions at New York University School of Medicine and the UCLA Center for Health Sciences — and is the author or co-author on 30 scientific publications.
Faculty Positions
- Stanford University — Guest Instructor (for courses on health policy and medical technology innovation
- University of California San Francisco — Guest Instructor (for courses on health policy and medical technology innovation)
- Harvard Medical School — Guest Speaker (Genomics, Value, Reimbursement: What Is Happening in the U.S.?)
- International Society for Pharmacoeconomics and Outcomes Research
- Association for Molecular Pathology
- Journal of Diabetes Science and Technology — Editorial Board, 2013-Present
- The Protecting Access to Medicare Act (PAMA) Insights
The Diagnostic Post Conference Webinar, November 2015
- Meeting the Challenges of Evidence and Coverage for Reimbursement: An Update
Opening Speaker, Integrating Personalized Medicine Into Health Care Summit, Washington, D.C., October 2015
- Evidence and Integration of Personalized Medicine Into Health Practice: Issues Faced by CMS
Panelist, Integrating Personalized Medicine Into Health Care Summit, Washington, D.C., October 2015
- Impact of PAMA Regulations on IVDs
Next Generation Dx Summit, Washington, D.C., August 2015
- Reimbursement for IVD Diagnostics: Rapid Policy Changes
Biodefense World Summit, Washington, D.C., May 2015
- Regulatory Challenges for Clinical Next Generation Sequencing
Morgan Stanley Life Sciences Conference, New York City, May 2015
- Reimbursement for Molecular Diagnostics
Diagnostics Global Marketing Summit, Boston, April 2015
- The FDA Lab Developed Test Guidance: Implications
Q1 Diagnostics Conference, San Diego, February 2015
- The Road to Precision Medicine
Patient-Centered Oncology Care, Baltimore, November 2014
- Ensuring Access to Innovative Diabetes Technologies
Diabetes Technology Innovation Summit, Stanford, Palo Alto, California, October 2014
- Implementation of CLFS Reforms: Key Considerations
BIO-PMC-NVCA Roundtable, Washington, D.C., May 2014
- Medicare Policy Changes
College of American Pathologist, House of Delegates Summit, Boston, April 2014
- Diabetes Technology Saves Money and Lives
13th Annual Diabetes Technology Meeting, San Francisco, October 2013
- An Overview of the Accountable Care Movement for Life Science Industry Professionals
National Webinar, Q1 Productions, September 2013
- Targeted Drugs, Stratified Patients: The Complex World of Combination Diagnostics
Managed Markets Conference, San Diego, September 2013
- Economics of Rare Disease Drug Development
Best Practices in Clinical Study Design in Rare Diseases, Washington, D.C., April 2013
- Changing Medicare Policy for Cancer Care
Ninth Annual Oncology Economics Summit, La Jolla, California, March 2013
- Health Care Reform and Personalized Medicine
Keynote Speaker, Molecular Diagnostics and Personalized Medicine, DECHEMA, Frankfurt, Germany, January 2013
- House of Lords Commission on Regenerative Medicine
California Institute for Regenerative Medicine, San Francisco, December 2012
- Regulatory and Reimbursement Outlook for Molecular Tests
Morgan Stanley Conference on Next Generation Sequencing, Boston, November 2012
- U.S. Health Care Policy and Diabetes
12th Annual International Diabetes Technology Conference, Bethesda, Maryland, November 2012
- Strategic Insights on Coverage With Evidence Development
Coverage with Evidence Development Workshop (MEDCAC), CMS, Baltimore, May 2012
- CMS Process and Reimbursement Tools
ADVAMED Medical Device Reimbursement Summit, Las Vegas, February 2012
- Medicare Coverage and Reimbursement
University of California San Francisco, From Idea to IPO (Steve Burrill, Course Director), February 2012
- Personalized Diagnostics in a Time of Rapid Change
Institute of Medicine, Workshop on Personalized Medicine, Washington, D.C., November 2011
- Navigating Through Emerging CMS Policies
Fifth Annual Device Reimbursement Conference, Chicago, July 2011
- Weathering the Perfect Storm: What You Need to Know About Impending Reimbursement, Regulation and Coding Reforms
National Webinar, Xifin, Inc., San Diego, July 2011
- The Seven Sins of Evidence Based Medicine
Scientia Advisors Luminary Series, Boston, June 2011
- From Translational Science to Commercialization
NMI Workshop, Tubingen, Germany, May 2011
- The Future of Drug Development in an Increasingly Evidence-based Environment and How Are Drugs and Biologics Paid for by Public and Private Payers?
UCSF/American Course on Drug and Regulatory Sciences, San Francisco, October 2010
- Emerging Importance of Companion Diagnostics in Drug Development
New York Academy of Sciences, September 2009
- Reimbursement Hurdles
Panelist, National Cancer Policy Forum (NCPF) Workshop: Policy Issues in the Development of Personalized Medicine in Oncology, Institute of Medicine of the National Academies, Washington, D.C., June 2009
- U.S. Payment Systems
European in Vitro Diagnostic Regulatory & Reimbursement Conference, Frankfurt, Germany, February 2009
- Preparing for the Next Frontier: Tailored Therapies and Smaller Faster Studies
American Conference 10 National Conference on Managing Legal Risks in Structuring & Conduction Clinical Trials, September 2008
- Implementing Personalized Medicine
American Association for the Advancement of Science (AAAS) and Food and Drug Law Institute (FDLI) Legal, Regulatory and Policy Seminar, Washington, D.C., June 2008
- Cost-effectiveness of Combinatorial Pharmacogenenomic Testing for Treatment-resistant Depression
American Journal of Managed Care (in press)
- The Future of Coverage and Payment for Personalized Medicine Diagnostics
White Paper, Personalized Medicine Coalition, 2014
- Molecular Diagnostics Clinical Utility Strategy: A Six-Part Framework
Co-author with Felix W. Frueh, Expert Reviews in Molecular Diagnostics, Vol. 14, No. 7, Pages 777-786, September 2014
- Diabetes Technology, Innovation and the U.S. Health Insurance System
Journal of Diabetes Science and Technology, Vol. 7, Issue 5, September 2013
- 2013-14: Evolving Challenges for Value-Priced LDTs
White Paper, 2013
- Is Medicare Zero for Three? Diagnostics Policy Proposals for CY201
White Paper, 2013
- Personalized Medicine: Reimbursement
Chapter co-author with Sean R. Tunis and Robert B. Giffin, Genomic and Personalized Medicine, Academic Press, 2012
- Rapid Changes in Reimbursement Protocols for Molecular Tests
Personalized Medicine in Oncology, 1:12-16
- Delivering the Promise of Personalized Medicine Diagnostics
Co-author with Susan Garfield and Meghan Gavaghan, Medical Laboratory Observer, November 2011
- Tempest in the Melting Pot: Genomics Reimbursement in 2012
White Paper, 2011
- Payers and the Assessment of Clinical Utility for Companion Diagnostics
Clinical Pharmacology and Therapeutics, 88:751-4, 2010
- Personalized Diagnostics: The Struggle for Position
Personalized Medicine, 7:263-73, 2010
- Coverage and Reimbursement for Molecular Diagnostics: Current Issues and Options
White Paper, 2008
- Crossing the Three Chasms: Complex Molecular Testing and Medicare Regulations
White Paper, 2008